Recent advances in radiotherapy for thoracic tumours

Journal of Thoracic Disease

Volumn 5, Issue SUPPL.5, 2013, Pages

  Fay, Michael ^a,b,c   Poole, Christopher M ^a,d   Pratt, Gary ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Advances; Radiotherapy; Review; Technology; Thoracic

Indexed keywords

BIOLOGICAL MARKER;

ADVANCED CANCER; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PLEURA MESOTHELIOMA; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; THERAPY EFFECT; THORAX TUMOR; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84899681567     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.08.46     Document Type: Review

References (42)

1. Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet 2011;378:1727-40.
2. Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with nonsmall-cell lung cancer: a prospective study. J Clin Oncol 2001;19:111-8.
3. O'Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol) 2000;12:141-4.
4. Everitt S, Plumridge N, Herschtal A, et al. The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer. Radiother Oncol 2013;106:288-91.
5. Kuo CH, Chen HC, Chung FT, et al. Diagnostic value of EBUS-TBNA for lung cancer with non-enlarged lymph nodes: a study in a tuberculosisendemic country. PLoS One 2011;6:e16877.
6. Chandarana H, Heacock L, Rakheja R, et al. Pulmonary Nodules in Patients with Primary Malignancy: Comparison of Hybrid PET/MR and PET/CT Imaging. Radiology 2013. [Epub ahead of print].
7. Schwenzer NF, Schraml C, Müller M, et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study. Radiology 2012;264:551-8.
8. Suzawa N, Ito M, Qiao S, Uchida K, et al. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Lung Cancer 2011;72:191-8.
9. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009;91:85-94.
10. Yaremko B, Riauka T, Robinson D, et al. Thresholding in PET images of static and moving targets. Phys Med Biol 2005;50:5969-82.
11. van Der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys 2005;61:649-55.
12. Knap MM, Hoffmann L, Nordsmark M, et al. Daily cone-beam computed tomography used to determine tumour shrinkage and localisation in lung cancer patients. Acta Oncol 2010;49:1077-84.
13. Meng LL, Feng LC, Wang YL, et al. Dosimetric comparison between helical tomotherapy and intensity-modulated radiation therapy plans for non-small cell lung cancer. Chin Med J (Engl)2011;124:1667-71.
14. Niyazi M, Landrock S, Elsner A, et al. Automated biological target volume delineation for radiotherapy treatment planning using FDG-PET/CT. Radiat Oncol 2013. [Epub ahead of print].
15. Dobbs HJ. Defining the radiation target on a daily basis. Cancer Imaging 2006;6:30-2.
16. Kong FM, Frey KA, Quint LE, et al. A pi lot study of [18F] fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.J Clin Oncol 2007;25:3116-23.
17. Kim DW, Chung WK, Shin D, et al. Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer. Radiat Oncol 2013;8:47.
18. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I nonsmall cell lung cancer. Chest 2003;124:1946-55.
19. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6.
20. Senan S. Surgery versus stereotactic radiotherapy for patients with earlystage non-small cell lung cancer: More data from observational studies and growing clinical equipoise. Cancer 2013;119:2668-70.
21. Dahele M, Pearson S, Purdie T, et al. Practical considerations arising from the implementation of lung stereotactic body radiation therapy (SBRT) at a comprehensive cancer center. J Thorac Oncol 2008;3:1332-41.
22. Senthi S, Haasbeek CJ, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 2013;106:276-82.
23. Hata M, Tokuuye K, Kagei K, et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys 2007;68:786-93.
24. Badiyan SN, Bierhals AJ, Olsen JR, et al. Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis. Radiat Oncol 2013;8:4.
25. Ball DL, Fisher R, Burmeister B, et al. Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol 2006;1:667-72.
26. Ball DL, Fisher RJ, Burmeister BH, et al. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol 2013;106:305-11.
27. Blumenschein GR Jr, Paulus R, Curran WJ, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/ B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011;29:2312-8.
28. Jensen AD, Münter MW, Bischoff H, et al. Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer 2006;6:122.
29. Vujaskovic Z, Groen HJ. TGF-beta, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol 2000;76:511-6.
30. Pang Q, Wei Q, Xu T, et al. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013;85:1332-9.
31. Das AK, Bell MH, Nirodi CS, et al. Radiogenomics predicting tumor responses to radiotherapy in lung cancer. Semin Radiat Oncol 2010;20:149-55.
32. Dai Y, Melzig C, Hanne J, et al. Combined ALK-inhibition and Radiation Therapy in Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier Inc, 2012;84:S706.
33. Zeng J, Aziz K, Chettiar ST, et al. Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. Int J Radiat Oncol Biol Phys 2013;86:143-9.
34. Ruben JD, Ball DL. The efficacy of PET staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. J Thorac Oncol 2012;7:1015-20.
35. Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2012;83:1278-83.
36. Patel PR, Yoo S, Broadwater G, et al. Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2012;83:362-8.
37. Ebara T, Kawamura H, Kaminuma T, et al. Hemithoracic intensitymodulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma. J Radiat Res 2012;53:288-94.
38. Chapman E, Berenstein EG, Diéguez M, et al. Radiotherapy for malignant pleural mesothelioma. Cochrane Database Syst Rev 2006;(3):CD003880.
39. Allen AM, Czerminska M, Jänne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006;65:640-5.
40. Parisi E, Sarnelli A, Giannini M, et al. Accelerated Hypofractionated Radiation Therapy Using Helical Tomotherapy for the Treatment of Medically Inoperable Pleural Mesothelioma: IRST Preliminary Data. International Journal of Radiation Oncology*Biology*Physics. Elsevier Inc, 2012;84:S578-S9.
41. Feigen M, Lee ST, Lawford C, et al. Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation. J Med Imaging Radiat Oncol 2011;55:320-32.
42. McCloskey P, Balduyck B, Van Schil PE, et al. Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer 2013;49:1555-64.